Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 study of oral formulation of Foralumab to healthy volunteers for the treatment of Crohn's disease

Trial Profile

A Phase 1 study of oral formulation of Foralumab to healthy volunteers for the treatment of Crohn's disease

Planning
Phase of Trial: Phase I

Latest Information Update: 01 Oct 2018

At a glance

  • Drugs Foralumab (Primary)
  • Indications Crohn's disease
  • Focus Adverse reactions
  • Most Recent Events

    • 01 Oct 2018 New trial record
    • 24 Sep 2018 According to a Tiziana Life Sciences media release, the company plans to submit an additional IND application to administer oral formulation of Foralumab the treatment of autoimmune and inflammatory diseases such as Crohn's disease.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top